Opinion: Intellectual property rights are not delaying coronavirus vaccines
OP ED - WASHINGTON POST
FINAL NIST Oral Testimony – John Stanford, Incubate
We're here today to lend our strong support to the proposed clarification of the appropriate use of "march-in" authority under Bayh Dole. This authority was never intended to be used a price-control mechanism, as such an interpretation would destabilize the IP protections that drive America's global biopharmaceutical leadership
Mergers and Acquisitions: A Key Driver of VC Investment in Healthcare
The drug pricing debate is a worthy one. We have to have open discussions about maximizing innovation and access. But half-written reports from a region that is home to the economic benefits of this industry do little to move that debate forward.
Bayh-Dole Coalition Urges the Biden Administration to Preserve the Bayh-Dole Act
March-In is Not the Answer
There is one strategy, however, that is likely to make things worse; overriding patents on drugs developed with the help of federally funded research. This so-called "march in" option is not a good idea.
Most Favored Nation (MFN) Model Interim Final Rule with Comment Period
Incubate writes to share our strong concerns with the interim final rule (IFR) implementing the Most Favored Nation (MFN) Model. We request the Biden Administration withdraw this rule.
Anti Microbial Resistance Whitepaper
From the Partnership to Fight Infectious Disease
Venture Capitalist Letter Addressing President Trump’s MFN EO
early stage life sciences community, write in strong opposition to the recently signed Executive Order (EO), Lowering Drug Prices by Putting America First.
Ensuring U.S. Biopharmaceutical Competitiveness
By Stephen Ezell, Information Technology and Innovation Foundation